Klus Pharma Inc.
Clinical trials sponsored by Klus Pharma Inc., explained in plain language.
-
New combo therapy targets multiple cancers in phase 2 trial
Disease control OngoingThis study tests a combination of two drugs, SKB264 and pembrolizumab, in 240 adults with advanced solid tumors like cervical, ovarian, prostate, and bladder cancers. The goal is to see if the combo shrinks tumors and is safe. Participants must have a life expectancy of at least …
Phase: PHASE2 • Sponsor: Klus Pharma Inc. • Aim: Disease control
Last updated May 26, 2026 10:00 UTC
-
New hope for lung cancer: experimental drug combo targets tumors
Disease control OngoingThis study tests an experimental drug called SKB264, given alone or with other treatments, for people with advanced or metastatic non-small cell lung cancer. The goal is to see if the drug is safe and can shrink tumors. About 356 adults with specific genetic types of lung cancer …
Phase: PHASE2 • Sponsor: Klus Pharma Inc. • Aim: Disease control
Last updated May 26, 2026 09:57 UTC
-
New hope for tough cancers: SKB264 trial targets tumors resistant to standard care
Disease control OngoingThis study tests a new drug called SKB264 in people with advanced solid tumors (like lung, breast, or ovarian cancer) that have not improved with standard treatments. The goal is to find the best dose and see if it can shrink tumors. About 1,410 participants will receive the drug…
Phase: PHASE1, PHASE2 • Sponsor: Klus Pharma Inc. • Aim: Disease control
Last updated May 19, 2026 12:01 UTC